Glucagon-like peptide-1 receptors in nucleus accumbens, ventral hippocampus, and lateral septum reduce alcohol reinforcement in mice.
Exp Clin Psychopharmacol · 2023
Last updated 2026-05-28In a mouse study, researchers found that injecting a GLP-1 drug called exendin-4 into specific brain areas—including the ventral hippocampus and lateral septum—reduced the animals' alcohol consumption. The same effect was seen when exendin-4 was injected into the nucleus accumbens, while injections into the caudate-putamen had little impact. The study suggests these brain regions play a key role in how GLP-1 drugs may help reduce alcohol intake.
AI summary of the abstract below.
| Journal | Exp Clin Psychopharmacol, 2023 |
|---|---|
| Citations | 20 |
| Relative citation ratio | 3.30 |
| NIH percentile | 86 |
| Molecules | — |
| Conditions studied | Alcohol Use Disorder |
Abstract
Glucagon-like peptide 1 (GLP-1) receptor agonists can decrease alcohol intake by central mechanisms that are still poorly understood. The lateral septum (LS) and the ventral/caudal part of the hippocampus are enriched in GLP-1 receptors, and activity in these regions was shown to modulate reward-related behaviors. Using microinfusions of the GLP-1 receptor agonist exendin-4 in mice trained to self-administer oral alcohol in an operant assay, we tested whether pharmacological stimulation of GLP-1 receptors in hippocampus and LS decrease alcohol self-administration. We report that infusion of exendin-4 in the ventral hippocampus or LS was sufficient to reduce alcohol self-administration with as large effect sizes as we previously reported with systemic exendin-4 administration. Infusion of exendin-4 into the nucleus accumbens also reduced alcohol self-administration, as anticipated based on earlier reports, while infusion of exendin-4 into the caudate-putamen (dorsal striatum) had little effect, consistent with lack of GLP-1 receptor expression in this region. The distribution of exendin-4 after infusion into the LS or caudate putamen was visualized using a fluorescently labeled ligand. These findings add to our understanding of the circuit-level mechanisms underlying the ability of GLP-1 receptor agonists to reduce alcohol self-administration. (PsycInfo Database Record (c) 2023 APA, all rights reserved).
Verbatim abstract via PubMed 36480394 ↗